Alternatives to Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach §130a Abs.8 SGB V zu verschiedenen Wirkstoff-/en/-kombinationen mit jederzeitiger Abschlussmöglichkeit im Rahmen des sog. Open House-Verfahrens

Germany – Vocational rehabilitation services – REZ SW UB AA Stuttgart

Germany – Pharmaceutical products – 61. Generika-Ausschreibung

Germany – Defibrillator – Rahmenvereinbarung zur Lieferung von Automatisierten externen Defibrillatoren und Zubehör für die unmittelbare und mittelbare Landesverwaltung Brandenburg

Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Guanfacin (ATC-Code: N06BA21).

Germany – Pharmaceutical products – Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2025-08

Germany – Pharmaceutical products – Arzneimittelrabattverträge gem. § 130a Abs. 8 SGB V im Rahmen von Open-House-Verfahren

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Entecavir (ATC: J05AF10 - in der Darreichungsform Filmtabletten)

Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-03

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Vilanterol und Umeclidiniumbromid (ATC: R03AL03)

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Irbesartan und Hydrochlorothiazid (ATC: C09DA24)

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Outcome: Successful proposals will contribute to the implementation of the EU initiative on Biotechnology and Biomanufacturing and the EU Life Sciences Strategy as well as the updated EU Bioeconomy Strategy, the upcoming EU Biotechnology Act and EU Circular Economy Act. Projects’ results are expected to contribute to the following expected outcomes: Full industrial scale biorefinery and related value chain(s) for the production of nutritional food ingredients. Resilience and strategic autonomy of EU food sectors via diversification of nutritional food ingredient sources. Increased environmental sustainability of food sectors (e.g. addressing issues like land use, water use, energy consumption, nitrogen cycle, other nutrients, etc.). Improved consumers awareness and acceptance of nutritional food ingredients from alternative sources, contributing to sustainable healthy diets. Scope: Human nutrition is a key area where the bio-based industries can play an important role in addressing the present societal and climate challenges. Considerable attention is given to the utilisation of alternative sources of proteins, fibres and oils/fats, due to the increasing world population…